Any disease not selected as measured (target) lesions should be considered not/non-measurable (non-target) lesions. These sites include any sites not selected as measurable or which do not meet the requirements for measurability but are still considered abnormal including:
- Nodes/nodal masses
- Extranodal sites of disease
- Assessable disease such as bone lesions, effusions, ascites or other truly non-measurable disease that are considered to be manifestations of lymphoma should be followed as non-target sites.
These sites should be assessed collectively for regression, stability and progression as a qualitative measure of response assessment.